REFRACTORY WALDENSTROM MACROGLOBULINEMIA
Clinical trials for REFRACTORY WALDENSTROM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY WALDENSTROM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY WALDENSTROM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug cocktail studied for rare blood cancer
Disease control TerminatedThis study tested a combination of two drugs, ibrutinib and ixazomib, in 21 people with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see if the combo could shrink tumors or stop the cancer from growing. The study was stopped early, so results are limited, b…
Matched conditions: REFRACTORY WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Experimental drug shows promise for rare blood cancer
Disease control TerminatedThis early-phase study tested the drug pomalidomide in 15 people with Waldenstrom macroglobulinemia, a rare blood cancer, that had returned or stopped responding to prior treatments. The main goal was to find the safest dose and watch for side effects. The study was stopped early…
Matched conditions: REFRACTORY WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC